Warsaw

• Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten (CK-3773274) in Adults With Hypertrophic Cardiomyo … Recruiting
  2023-508963-58-00 4 2022-01-31 Symptomatic hypertrophic cardiomyopathy (HCM)
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim … Recruiting
  2024-510690-16-00 5 2022-01-31 Relapsed/refractory follicular lymphoma
• Phase 1 trial of trametinib and gilteritinib for the treatment of relapsed or refractory acute leukemia patients Recruiting
  2024-518301-18-00 3 2022-01-28 Relapsed and/or refractory acute lymphoblastic (ALL) or myeloid (AML)
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• A multicentre study evaluating the safety of reperfusion thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtP … Recruiting
  2024-518509-17-00 4 2022-01-10 Acute ischemic stroke
• Phase 1 Study of MK-1084 in KRAS mutant advanced solid tumors Recruiting
  2022-501563-40-00 1 2021-12-16 Solid tumor cancer and lung cancer
• A study to investigate the safety and tolerability of Trastuzumab Deruxtecan in combination with Immunotherapy Agents with and without chemo … Recruiting
  2023-504949-31-00 3 2021-12-01 Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) wit
• Efficacy and Safety Study of Nipocalimab IV Infusions for Adults With Generalized Myasthenia Gravis Recruiting
  2023-504152-97-00 5 2021-11-26 Generalized Myasthenia Gravis
• Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasth … Recruiting
  2024-513854-31-00 10 2021-10-27 Generalized Myasthenia Gravis
• DZR123 (CPI-0209) in Patients with Advanced Solid Tumors and Lymphomas Recruiting
  2023-508002-20-00 7 2021-10-21 advanced, solid, relapsed tumors / advanced tumors: human lymphomas /
• A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC) Recruiting
  2023-505163-37-00 3 2021-10-01 Metastatic Colorectal Cancer
• Comparison of the efficacy and safety of rapamycin versus vigabatrin in the prevention of Tuberous Sclerosis Complex symptoms in infants in … Recruiting
  2024-513068-25-00 10 2021-05-20 Tuberous Sclerosis Complex, Epilepsy, Tumors associated with Tuberous
• To check the safety, efficacy and tolerability of the drug vemurafenib, and to determine the duration of treatment in children with BRAF mut … Recruiting
  2024-515805-25-00 4 2021-05-13 histiocytic cell proliferation
• A Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects with Moderate to … Recruiting
  2022-502519-13-00 5 2021-05-07 Moderate to Severe Plaque Psoriasis
• Examination of the molecular profile in adolescent patients with histiocytic cell hyperplasia, and if a specific mutation is detected, its m … Recruiting
  2024-515895-11-00 6 2021-04-15 histiocytic cell proliferation
• A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies Recruiting
  2023-504931-42-00 4 2021-04-06 Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters tran
• Apremilast Study in Children with Active Juvenile Psoriatic Arthritis Recruiting
  2023-503435-17-00 5 2021-03-31 Juvenile psoriatic arthritis
• Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negativ … Recruiting
  2024-515063-66-00 4 2021-03-30 Early stage classical Hodgkin Lymphoma (cHL) without bulky lesions and
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• PHASE I STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE FOR TRICHOSTATIN A IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES Recruiting
  2024-518454-17-00 1 2021-01-08 relapsed/refractory hematologic malignancies
• An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the i … Recruiting
  2023-504417-67-00 6 2020-12-22 Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Sp
• A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or … Recruiting
  2023-504888-16-00 9 2020-10-05 Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressi
• Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced … Recruiting
  2023-509846-36-00 9 2020-05-29 Advanced Solid Tumors
• Pan tumor Roll Over Study Recruiting
  2023-506914-32-00 4 2020-05-05 Pan tumor

Showing 745–768 of 1,708 trials